Biofrontera Inc.
Biofrontera Inc. Q4 FY2024 earnings call
March 21, 2025 · fiscal period ended 2024-12
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2025-03-21
Management highlights
• 2024 milestones: Placed 100 RotoLite XL lamps by end of 2024, obtained FDA approval to use up to three tubes of Ameluz per treatment, achieved results in phase three study of Ameluz for superficial basal cell carcinoma, negotiated restructuring with Biofrontera AG reducing transfer price to 25% for 2024-2025, took control of clinical trials in USA, recruited final patient in phase three study for actinic keratosis on trunk, neck, extremities, ongoing phase two study for acne close to completing patient recruitment. • Financial improvements: Lower transfer pricing, reduced SG&A expenses, increased revenues due to higher volume and new lamp launch.
Segment performance
Fourth quarter 2024 total revenues were $12.6 million, an increase of $2.0 million or 18.5% compared to Q4 2023. Full year 2024 total revenues were $37.3 million, an increase of approximately 9.5% from 2023. Cost of revenues for Q4 2024 was $5.3 million vs $5.4 million prior year; full year cost of revenues was $18.6 million vs $17.4 million. Selling, general, and administrative expenses for Q4 2024 were $8.2 million vs $9.1 million prior year; full year SG&A decreased by $5.3 million or 13.5%. Net loss for Q4 2024 was $1.4 million vs net income of $3.5 million prior year; full year net loss was $17.8 million vs $20.1 million. Adjusted EBITDA for Q4 2024 was negative $1.4 million vs negative $3.2 million prior year; full year adjusted EBITDA was negative $15.3 million vs negative $19.5 million.
Guidance
• Expect another record year in 2025. • Transfer price of 25% continues through 2025. • SG&A expected to hold steady in 2025.
Q&A highlights
Q: What was the Q4 2024 Ameluz unit growth year over year?
A: Approximately 2% Q: Any sales force addition or attrition in 2024?
A: Commercially, held approximately constant Q: Acne enrollment number and data timing?
A: Enrollment number is 116, may conclude trial a bit earlier Q: Impact of advantageous transfer pricing on gross margins in 2025?
A: Transfer price of 25% through 2025, almost exclusively at lower price in 2025 Q: Price increase percentage in Q4 2024 and effect on forward buying?
A: 5% price increase, customers did a bit of buy-in before price increase Q: Trend of SG&A and R&D in 2025?
A: SG&A expected to hold steady, R&D stable
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-2.33 | $0.02 | -11750.0% | — |
| Revenue | $12.6M | $10.5M | +19.5% | — |
Transcript
March 21, 2025Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.